You are on page 1of 1

June 7, 2017

Statement on
Johnson & Johnson Innovation and Pharmaceutical R&D Leadership Appointments

Johnson & Johnson has a longstanding legacy in innovation. Over the past decade, our Janssen
Pharmaceutical business has become one of the most productive pharmaceutical organizations
globally, admired and respected for our industry-leading pipeline and our focus on patients.

In the past few years, we also have created an external innovation engine and a global innovation
network that has positioned us as the partner of choice across the globe.

Sustaining our strong leadership and growth in Pharmaceuticals, while exploring new frontiers
and creating additional value for the enterprise portfolio through external innovation and funding,
is a critical part of our growth strategy and our mission to improve patients lives.

To this end, we are pleased to confirm the appointment of William N. Hait, M.D., Ph.D., Global
Head, Janssen R&D, to a newly created company-wide R&D role of Global Head, Johnson &
Johnson External Innovation overseeing Johnson & Johnson Innovation (including the
Innovation Centers, JLABS and JJDC), our enterprise cross-sectors initiatives (lung cancer,
obesity) and the World Without Disease strategy, effective January 1, 2018.

With Dr. Hait taking on enterprise responsibilities, we are pleased that Mathai Mammen, M.D.,
Ph.D. will succeed him as Global Head, Janssen Research & Development, LLC, effective
January 1, 2018. Dr. Mammen joins us from Merck Research Laboratories on June 26, 2017. He
will transition into his new role over the course of 2017 and fully take over Janssen R&D
leadership from Dr. Hait on January 1, 2018, at which point he will report directly to Paul Stoffels.

Dr. Mammen is a highly experienced and passionate R&D and business leader who has helped
create two pharmaceutical companies. He was personally responsible for developing three
products approved in 5 indications. Dr. Mammens focus on research, his entrepreneurship, his
extensive experience in drug development, and his commitment to talent will provide the Janssen
R&D organization with leadership for continued success in the future.

In his 10 years at Johnson & Johnson, Dr. William Hait played a significant role in transforming
the pharmaceutical business, first creating an outstanding oncology drug portfolio for Janssen. He
went on to lead Janssen R&D through a period of continued productivity and growth, building a
sustainable industry-leading pipeline. In his new role, Dr. Hait will help Johnson & Johnson
accelerate and maximize value creation of our portfolio sourced through external innovation, and
to deliver on the cross-sector initiatives and our World Without Disease vision.

These leadership appointments position Johnson & Johnson for sustaining our leadership in
bringing transformational innovations to people globally as well as driving growth for our business.

Paul Stoffels, M.D.


Chief Scientific Officer
Johnson & Johnson